Immuno-Oncology | Specialty

Evidence Builds for Targeting PD-1/PD-L1 Pathway in Bladder Cancer

March 21st 2017

As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.

Dr. Luke on Adjuvant Therapies in Development for Melanoma

March 20th 2017

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial

March 20th 2017

Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

March 19th 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Expert Examines Clues to Deploying Immunotherapy in Breast Cancer

March 18th 2017

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

Expert Discusses Promise of Immunotherapy in TNBC

March 17th 2017

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

The Future of Bladder Cancer Research

March 16th 2017

Bladder Cancer: Monoclonal Antibodies Under Investigation

March 16th 2017

BCG-Refractory Superficial Bladder Cancer

March 16th 2017

Bladder Cancer: Immunotherapy in the Perioperative Setting

March 16th 2017

Combination Trials in Advanced Bladder Cancer

March 16th 2017

Immunotherapy Toxicity Management in Bladder Cancer

March 16th 2017

Update on Durvalumab for Metastatic Bladder Cancer

March 16th 2017

Chemotherapy Following Immunotherapy in Bladder Cancer

March 16th 2017

Activity of Immunotherapy in the Frontline Setting

March 16th 2017

Bladder Cancer: Real-World Experience With Immunotherapy

March 16th 2017

FDA Approval of Atezolizumab for Advanced Bladder Cancer

March 16th 2017

PD-L1 Expression in Bladder Cancer

March 16th 2017

Prognostic Subgroups in Advanced Bladder Cancer

March 16th 2017

Historic Perspective on Treatment of Bladder Cancer

March 16th 2017